.webp&w=828&q=75)
Elixir Energy’s Lorelle-3H result showed encouraging gas flow, but investors still want proof of sustained production, commercial recovery and pipeline access. The sharp chart breakdown leaves EXR oversold, speculative and dependent on October’s retest.
.webp&w=828&q=75)
Ramelius Resources delivers record free cash flow and sustained production growth, reinforcing its position as a high‑grade, low‑cost gold producer with strong shareholder returns and expansion upside.

Global Lithium Resources is advancing Manna-Nova integration to target DSO in early 2027 and spodumene concentrate by mid-2027. Nova infrastructure, offtake, prepayment funding and asset-sale proceeds strengthen its pathway to FID, although permitting, funding, execution and lithium-price risks remain.
.webp&w=828&q=75)
Iluka Resources (ASX: ILU) advances its Eneabba rare earth refinery and Balranald ramp‑up, positioning as Australia’s critical minerals leader with strong government backing and margin resilience through 2026
.webp&w=828&q=75)
Larvotto Resources enters a key operational phase as Hillgrove commissioning begins, copper expansion progresses, and the weekly chart tests important support and resistance levels while investors watch execution and future growth catalysts.

BLS Pharmaceuticals has rapidly transformed into a profitable regulated-medicines manufacturer, supported by strong revenue growth, controlled-substance licences and international expansion. While FY26 guidance remains ambitious, bearish RSI divergence suggests traders should monitor key support levels closely.